ACET Stock — Adicet Bio Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. We are advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.05

Market cap

$28.6M

Cash

$100.9M

Enterprise value

-$72.3M

Balance sheet

Cash	$100.9M
Debt	$0.0M
Net cash	$100.9M
Enterprise value	-$72.3M
Basic shares	9.4M shares
Fully diluted shares	12.8M shares
Fully diluted market cap	$39.0M
Cash per share	$10.78
Quarterly burn	$19.8M
Cash runway	6.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

9.4M

Pre-funded warrants

1.4M

Options

1.7M

RSUs

0.1M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.2M

FDSO

12.8M

Cap table as of 2026-06-30.

Price history

Loading ACET daily closes…

Loading price history…

Next catalyst

ADI-270 · Jan 12 - Feb 23 in 9 wks · Phase 1/2 · Clear Cell Renal Cell Carcinoma

Recently reported

ADI-001 Phase 1 Positive · 2026-09-28

ADI-001 · lupus nephritis, autoimmune diseases, systemic sclerosis (ssc)

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 9 wks	ADI-270	Phase 1/2	Clear Cell Renal Cell Carcinoma	—
May 11 - Jun 22 in 6 mo	ADI-001	Phase 1	Rheumatoid Arthritis (RA)	—
Nov 12 - Dec 24 in 25 mo	ADI-212	Phase 1/2	Prostate Cancer Metastatic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Prula-cel

Phase 1 · Active Modality: allogeneic gamma delta CAR T cell therapy

Aliases prulacabtagene leucel, ADI-001

Target CD20

Indications

Lupus nephritis (LN) (Phase 1)
Systemic lupus erythematosus (SLE) (Phase 1)
Systemic sclerosis (SSc) (Phase 1)
ANCA-associated vasculitis (AAV) (Phase 1)
Idiopathic inflammatory myopathy (IIM) (Phase 1)
Stiff person syndrome (SPS) (Phase 1)
Rheumatoid arthritis (RA) (Phase 1)

Catalysts

— first half of 2026
— second half of 2026
— second half of 2026
— second half of 2026

Status note Lead product candidate. FDA Fast Track Designation: LN (Jun 2024), refractory SLE with extrarenal involvement and SSc (Feb 2025).

ADI-212

Preclinical · Active Modality: gene-edited and armored allogeneic gamma delta CAR T cell therapy (membrane-tethered IL-12 armoring, CRISPR/Cas9 MED12 disruption)

Target PSMA (prostate-specific membrane antigen)

Indications

Metastatic castration-resistant prostate cancer (mCRPC) (Preclinical)

Catalysts

— third quarter of 2026
— fourth quarter of 2026

Status note Next-generation candidate; company aims to submit a new IND or equivalent every 12-18 months.

ADI-270

Phase 1 · Terminated Modality: allogeneic gamma delta CAR T cell therapy

Indications

Metastatic/advanced clear cell renal cell carcinoma (ccRCC) (Phase 1)

Status note Development discontinued July 2025 per strategic pipeline prioritization; enrollment in Phase 1 ccRCC trial closed.

ADI-002

Stage not disclosed · Active Modality: allogeneic gamma delta CAR T cell therapy

Target Glypican-3

Partnerships Regeneron: $20M option exercise fee (Jan 2022); high single-digit royalties on net sales

Status note Regeneron-licensed program; Regeneron solely responsible at its sole cost for all development, manufacturing and commercialization.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06480565	Phase 1/2	Active, not recruiting	Sponsor	Adicet Therapeutics	—	Clear Cell Renal Cell Carcinoma	—
NCT07793435	Phase 1/2	Not yet recruiting	Sponsor	Adicet Therapeutics	—	Prostate Cancer Metastatic	—
NCT06375993	Phase 1	Enrolling by invitation	Sponsor	Adicet Therapeutics	—	Lupus Nephritis; Autoimmune Diseases; Systemic Sclerosis (SSc)	September 2026 Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT07100873	Phase 1	Recruiting	Sponsor	Adicet Therapeutics	—	Rheumatoid Arthritis (RA)	—
NCT04911478	Not disclosed	Active, not recruiting	Sponsor	Adicet Therapeutics	—	Lymphoma, Follicular; Lymphoma, Mantle-Cell; Marginal Zone Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Adicet Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	932,624	-250,000	0.07%	2026-08-14
OrbiMed Advisors	844,787	-183,157	0.14%	2026-08-14
Stonepine Capital	245,518	+23,563	1.61%	2026-08-17
DAFNA Capital	93,812	no change	0.15%	2026-08-14
ADAR1 Capital Management	0	-53,827	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ACET — Adicet Bio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

ACET — Adicet Bio Inc.